Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
The latest announcement is out from NFL Biosciences SA ( (FR:ALNFL) ).
NFL Biosciences announced positive results from a toxicity study of its drug NFL-101, which is used for treating tobacco addiction. The study, which tested doses 630 times greater than the cumulative dose assessed in humans, confirmed the drug’s excellent safety profile, showing no signs of systemic or local toxicity. This outcome enhances NFL-101’s benefit-risk ratio and supports ongoing regulatory discussions for Phase 3 development. The results also position NFL-101 as a potentially superior alternative to existing tobacco addiction treatments, reinforcing NFL Biosciences’ discussions with industrial partners.
More about NFL Biosciences SA
NFL Biosciences is a biopharmaceutical company based in Montpellier, specializing in the development of botanical drug candidates for addiction treatment. The company aims to provide natural, safe, and effective therapeutic solutions globally, including to low- and middle-income countries, with products like NFL-101 for tobacco addiction and NFL-301 for reducing alcohol consumption.
YTD Price Performance: -8.18%
Average Trading Volume: 400
Technical Sentiment Consensus Rating: Buy
Learn more about ALNFL stock on TipRanks’ Stock Analysis page.